The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2023

Filed:

Jul. 08, 2016
Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Koichi Jishage, Shizuoka, JP;

Otoya Ueda, Shizuoka, JP;

Naoko Wada, Shizuoka, JP;

Takahiro Ishiguro, Tokyo, JP;

Yasuko Kinoshita, Kanagawa, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); C12N 15/85 (2006.01); C12N 15/09 (2006.01); G01N 33/50 (2006.01); G01N 33/15 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C12N 15/8509 (2013.01); G01N 33/15 (2013.01); G01N 33/5008 (2013.01); A01K 2207/12 (2013.01); A01K 2217/072 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0325 (2013.01); A01K 2267/0331 (2013.01); C12N 15/09 (2013.01); C12N 2015/8518 (2013.01);
Abstract

The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3ε, CD3δ, and CD3γ in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3ε, CD3δ, and CD3γ. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.


Find Patent Forward Citations

Loading…